[Pharmacokinetics of three peroral dosage forms of new dipeptide anxiolytic drug GB-115].

Comparative analysis of the pharmacokinetics and bioequivalence of a new dipeptide anxiolytic compound GB-115 in three drug forms for peroral administration, developed in the experimental technology department of the Institute of pharmacology RAMS, was carried out. Three drug forms of GB-115 and a micronized substance of this compound were different in composition and technology of production. As a result of the investigations of GB-115 pharmacokinetics, drug form No. 2 (with a relative bioequivalence of 192%) showed advantages in comparison to the micronized parent substance and two other drug forms (bioequivalence, 53 and 117%) and can be recommended for further pharmacological studies.